


Curriculum Vitae

Name	Tadakazu Hisamatsu	
Country	Japan	
Organization	Kyorin University School of Medicine	
Current Position	Professor	

Educational Background

October 2003: Ph.D, Keio University School of Medicine,
March 1991: M.D., Keio University School of Medicine,
March 1985: Keio Senior High School

Professional Experience

Apr 2019-date: Professor of Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
Apr 2016: Chief of Division of Gastroenterology and Hepatology, Chief of Endoscopy Unit
Apr 2015: Professor, Division of Gastroenterology and Hepatology, The Third Department of Internal Medicine, Kyorin University School of Medicine
Apr 2008: Assistant Prof, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine
Jun 2000: Fellow researcher, Department of Gastroenterology, Massachusetts General Hospital, Harvard Medical School (U.S.A.)
June 1991: Resident, Department of Internal Medicine, Keio University Hospital

Professional Organizations

Secretary General, a member of the board of directors, Japanese Society for Inflammatory Bowel Disease (J SIBD)
Educational Committee member of AOCC

Main Scientific Publications

- Adedokun OJ, **Hisamatsu T**, Sandborn WJ et al.. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC. *Clin Gastroenterol Hepatol*. 2019 Dec 6.
- Sands BE, **Hisamatsu T**, Marano C et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med*. 2019 Sep 26;381(13):1201-1214.
- Saito D, **Hisamatsu T** et al. MEFV Gene-Related Enterocolitis Account for Some Cases Diagnosed as Inflammatory Bowel Disease Unclassified. *Digestion*. 2019 Sep 6:1-9. *J Gastroenterol Hepatol*. 2019 Aug 8.
- Ooi CJ, **Hisamatsu T**, et al. Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. *Intest Res*. 2019 May 31.

-
- ◆ **Hisamatsu T**, Kato S, Matsumoto T, et al. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). *J Gastroenterol*. 2019 Apr 30.
 - ◆ **Hisamatsu T**, Matsumoto T, Hibi T, et al; DIAMOND study group. Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study). *J Crohns Colitis*. 2019 Feb 8.
 - ◆ Ooi CJ, **Hisamatsu T**, et al. Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. *Intest Res*. 2019 May 31.
 - ◆ Watanabe K, Matsumoto T, **Hisamatsu T**, et al; DIAMOND study group. Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn's disease. *Clin Gastroenterol Hepatol*. 2017 Nov 2.
 - ◆ Nakase H, **Hisamatsu T**, Hibi T, et al; DIAMOND study group. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. *Aliment Pharmacol Ther*. 2017 Sep 8.
 - ◆ **Hisamatsu T**, Hayashida M. Treatment and outcomes: Medical and surgical treatment for intestinal Behçet's disease. *Intest Res* 2017; 15(3): 318-327
 - ◆ Matsumoto T, Motoya S, Watanabe K, **Hisamatsu T**, et al. Diamond Study Group. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: A prospective, randomized trial. *J Crohns Colitis*. 2016 Nov;10(11):1259-1266.
 - ◆ Umeno J, **Hisamatsu T**, et al. A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter. *PLoS Genetics* 2015 Nov 5;11(11):e1005581.
 - ◆ Uo M, **Hisamatsu T**, Hibi T, et al. Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14+ macrophage activation. *Gut*. 2013 Dec;62(12):1734-44.
 - ◆ Kamada N, **Hisamatsu T**, Honda H, Kobayashi T, Chinen H, Takayama T, Kitazume MT, Okamoto S, Koganei K, Sugita A, Kanai T, Hibi T. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. *Inflamm Bowel Dis*. 2010 Apr;16(4):568-75.
 - ◆ Kamada N, **Hisamatsu T**, Honda H, Kobayashi T, Chinen H, Kitazume M, Takayama T, Okamoto S, Koganei K, Sugita A, Kanai T, Hibi T. Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen presenting ability. *J Immunol*. 2009 Aug 1;183(3):1724-31.
 - ◆ Andou A, **Hisamatsu T**, Okamoto S, Chinen H, Kamada N, Kobayashi T, Hashimoto M, Okutsu T, Shimbo K, Takeda T, Matsumoto H, Sato A, Ohtsu H, Suzuki M, Hibi T. Dietary Histidine Ameliorates Murine Colitis by Inhibition of Proinflammatory Cytokine Production from Macrophages. *Gastroenterology*. 2009 Feb;136(2):564-74.
 - ◆ Kamada N, **Hisamatsu T**, Hibi T, et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN- γ axis. *J Clin Invest*. 2008 Jun;118(6):2269-80.
 - ◆ **Hisamatsu T**, Suzuki M, Podolsky DK, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. *Gastroenterology*. 2003 Apr;124(4):993-1000.
-